Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

eroconversion compared with 25 percent (n=5/20) adefovir-treated

patients.

-- Six BARACLUDE(R) (entecavir)-treated patients and 16 adefovir-treated

patients discontinued therapy prior to week 96.

- No BARACLUDE-treated patients and one adefovir-treated patient

discontinued due to adverse events.

- No BARACLUDE-treated patients and six adefovir-treated patients

discontinued due to investigator-determined treatment failure or lack

of efficacy.

- Three BARACLUDE-treated patients and four adefovir-treated patients

met the treatment response criteria at 52 weeks and entered a 24- or

48-week off-treatment follow-up monitoring phase.

- Two BARACLUDE-treated patients and one adefovir-treated patient were

lost to follow-up, one BARACLUDE-treated patient was non-compliant,

two adefovir-treated patients withdrew consent, one adefovir-treated

patient became pregnant, and one adefovir-randomized patient was

treated with BARACLUDE.

Week 12 (primary endpoint)

-- BARACLUDE-treated patients achieved a mean change in viral load of

-6.23 log(10) copies/mL from baseline, compared to adefovir-treated

patients who achieved a mean change of -4.42 log(10) copies/mL

(p < 0.0001).

-- 12 percent of BARACLUDE-treated patients and 9 percent of

adefovir-treated patients had undetectable viral load (HBV DNA <300

copies/mL).

Additional Cumulative Safety Results of the E.A.R.L.Y. Study at 96 Weeks

-- 83 percent of patients in the BARACLUDE arm (n=30) and 82 percent of

patients in the adefovir arm (n=27) experienced any adverse event.

-- Eight percent of patients receiving BARACLUDE (n=3) and 15 percent of

patients receiving adefovir (n=5) experienced any Grade 3-4 adverse

event.

-- Three percent of patients receiving BARACLU
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) ... previously announced acquisition of SloMedical S.R.O., a ... ranging from tubing sets to complex devices ... Flextronics provides a broad set of capabilities ... customers. Terms of the deal were not ...
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... Dec. 15 Certified healthcare providers who ... complications from the H1N1 flu virus may now ... the Department of Health announced today. ,, ... everyone because approximately 3.2 million doses of vaccine ... it to individuals in the priority groups. ,, ...
Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Upending textbook science on Alzheimers disease 61940 1Upending textbook science on Alzheimers disease 61940 2Killer fungus threatening amphibians 10867 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 3
... Use of Fujirebio Diagnostics, , HE4 Test with CA125 ... Pa., Jan. 26 A pivotal clinical trial published ... Gynecologic Oncology demonstrated the utility of combining Fujirebio ... in estimating the risk of epithelial ovarian cancer in ...
... Identified, Versus MenNEW YORK, Jan. 26 Hypertrophic Cardiomyopathy ... thickening of the heart wall muscle and is the ... young adults (<40). More importantly, although heart disease ... Cardiomyopathy Association ( www.4HCM.org ) warns women remain untreated ...
Other Medicine Technology:Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 2Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 3Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 4Cardiac Disease in Women Remains Untreated for Decades 2
(Date:12/15/2009)... 15 SUMMARY: The U.S. ... Protection and Affordable Care Act that would have ... for the safe and legal importation of lower ... by AARP and sponsored by Senators Dorgan, Snowe, ... and helped to bring down the skyrocketing costs ...
(Date:12/15/2009)... (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization ... all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders ... Description of Votes ... Votes Non-, Matter ... For Against ...
(Date:12/15/2009)... Calif., Dec. 15 Palo Alto Networks(TM), ... University has deployed its PA-4000 Series next-generation firewalls ... and for enhanced visibility and control over applications ... is a Japanese national university with eight facilities ... 1949 by integrating a number of academic schools ...
(Date:12/15/2009)... be donated to the Lupus Foundation of America and ... Dec. 15 Julian Lennon, son of the ... their new digital single, "LUCY," to raise funds for ... 15, 2010, 100 percent of the proceeds from downloading ... Foundation of America (LFA), and the Saint Thomas, Lupus ...
(Date:12/15/2009)... YORK, Dec. 15 Vitech Systems Group, ... Relationship Management (CRM) software, announced today that it ... implementation for the Screen Actors Guild-Producers Pension & ... advanced customer service capabilities to SAG-PH call center ... system was installed using Vitech,s V3 Benefits Administration ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2
... disease care, study finds , , TUESDAY, Oct. 2 (HealthDay ... rates of chronic disease in the United States, with ... a new study finds. , It,s an expensive problem, ... and heart disease account for some $100 to $150 ...
... MIT Holding, Inc. (OTCBB: MITD - News), has signed ... to stop the spread of infectious diseases. Dr. ... and Director of the Biodefense and Infectious Disease Laboratory ... College of Public Health, Georgia Southern University, will oversee ...
... PA, October 2, 2007 The first significant genetic ... reported. PMDD is a very severe form of ... PMDD is heritable, affects 5-8% of women, and is ... irritability, marked depressed mood, anger, headaches, weight gain and ...
... /PRNewswire/-- Meretek Diagnostics, Inc. and,Otsuka America Pharmaceutical, Inc. ... the two companies. The merger forms a new ... America Pharmaceutical,Inc. OAPI was established in 1989 ... by Otsuka Pharmaceutical Co., Ltd. (OPC). Meretek Diagnostics,was ...
... Fibertec, a division of,Filtrona plc, developer of fiber-based ... celebrated the completion,of the recent expansion of its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ) The ... the size of,production floor space and an expanded ...
... TOWN, W.V., Oct. 2 /PRNewswire-FirstCall/-- ReBuilder Medical,Technologies, Inc. ... the,increasing demand for its products it has had ... in the past three weeks alone. (Logo: ... PhD, CEO of ReBuilder, stated, "We have been,marketing ...
Other Medicine News:Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger 2Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: